European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals
Background Evaluating COVID-19 vaccine coverage and risk factors is useful to develop public health strategies against COVID-19 pandemic. In the framework of two studies commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Epiconcept, France, we reported f...
Gespeichert in:
| Veröffentlicht in: | European journal of public health 2022-10, Vol.32 (Supplement_3) |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_3 |
| container_start_page | |
| container_title | European journal of public health |
| container_volume | 32 |
| creator | Agodi, A Rapisarda, V Bonfanti, P Rossi, M De Gaetano Donati, K Murri, R Barchitta, M |
| description | Background
Evaluating COVID-19 vaccine coverage and risk factors is useful to develop public health strategies against COVID-19 pandemic. In the framework of two studies commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Epiconcept, France, we reported findings about incidence and seroprevalence among healthcare workers (HCWs) enrolled from three Italian hospitals.
Methods
From July 2021 to date, the AOUP "G. Rodolico-San Marco" (Catania), the San Gerardo Hospital (Monza) and the Policlinico Gemelli (Rome) participated in the ECDC study to measure COVID-19 vaccine effectiveness. Catania and Rome also participated to the ECDC study of nosocomial transmission. HCWs were asked to complete a weekly questionnaire to report changes in health status and professional/personal exposures. At recruitment, a nasopharyngeal swab for RT-PCR and a blood sample for serology test were collected. Moreover, HCWs were followed-up with a weekly or bimonthly nasopharyngeal or saliva swabs. Blood samples were collected every one or two months.
Results
A total of 226 HCWs was enrolled from Catania, 330 from Rome and 132 from Monza in the COVID-19 vaccine effectiveness study. As of February 2022, PCR tests performed were 2270 in Catania, 5475 in Rome and 891 in Monza sites. Moreover, the serological tests performed were 845 in Catania, 760 in Rome and 395 in Monza sites. A total of 6 SARS-CoV-2 infections were identified in Catania, 34 in Rome and 4 in Monza sites. Interestingly, the study of nosocomial transmission reported the highest incidence rate in Catania (4 per 10,000 person-day), while 0.7 per 10,000 person-day in Rome. During the study period seroprevalence declined by 17% among HWCs enrolled in Catania.
Conclusions
Our findings revealed low number of COVID-19 infections, with high COVID-19 vaccine coverage among HCWs. However, further analyses are needed to provide more robust estimates of vaccine effectiveness.
Key messages
Monitoring risk factors is useful to understand the pandemic scenario among high-risk groups.
A larger sample size and follow-up will improve public health vaccination strategies against COVID-19. |
| doi_str_mv | 10.1093/eurpub/ckac130.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2854903459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurpub/ckac130.021</oup_id><sourcerecordid>2854903459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1531-ac6757fb8a65525250bdef988642e7809c02bdace869ea2f5ccf222fceb91abf3</originalsourceid><addsrcrecordid>eNqNkM1OwzAQhC0EEqXwApwscXZrO3ESc0Oh0EqVeuHvZjnuWqS0cbDjSrw9RukDoD3MHGZmpQ-hW0ZnjMpsDtH3sZmbL21YRmeUszM0YXmRk6ygH-fJM8oI4wW_RFch7Ciloqz4BJlF9K4H3eEwxG0LAQ8Ow1Hvox4A15u31SNhEh-1MW0HGKwFM7RH6CAE3HZ4Wb-He-whxP0QsPXugFeD3rdp8NOFvk0-XKMLmwRuTjpFr0-Ll3pJ1pvnVf2wJoaJjBFtilKUtql0IQRPR5stWFlVRc6hrKg0lDdbbaAqJGhuhTGWc24NNJLpxmZTdDfu9t59RwiD2rnou_RS8Urkkma5kCnFx5TxLgQPVvW-PWj_oxhVfzDVCFOdYKoEM5XIWHKx_0_-Fz8ueqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2854903459</pqid></control><display><type>article</type><title>European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals</title><source>DOAJ Directory of Open Access Journals</source><source>PAIS Index</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Agodi, A ; Rapisarda, V ; Bonfanti, P ; Rossi, M ; De Gaetano Donati, K ; Murri, R ; Barchitta, M</creator><creatorcontrib>Agodi, A ; Rapisarda, V ; Bonfanti, P ; Rossi, M ; De Gaetano Donati, K ; Murri, R ; Barchitta, M</creatorcontrib><description>Background
Evaluating COVID-19 vaccine coverage and risk factors is useful to develop public health strategies against COVID-19 pandemic. In the framework of two studies commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Epiconcept, France, we reported findings about incidence and seroprevalence among healthcare workers (HCWs) enrolled from three Italian hospitals.
Methods
From July 2021 to date, the AOUP "G. Rodolico-San Marco" (Catania), the San Gerardo Hospital (Monza) and the Policlinico Gemelli (Rome) participated in the ECDC study to measure COVID-19 vaccine effectiveness. Catania and Rome also participated to the ECDC study of nosocomial transmission. HCWs were asked to complete a weekly questionnaire to report changes in health status and professional/personal exposures. At recruitment, a nasopharyngeal swab for RT-PCR and a blood sample for serology test were collected. Moreover, HCWs were followed-up with a weekly or bimonthly nasopharyngeal or saliva swabs. Blood samples were collected every one or two months.
Results
A total of 226 HCWs was enrolled from Catania, 330 from Rome and 132 from Monza in the COVID-19 vaccine effectiveness study. As of February 2022, PCR tests performed were 2270 in Catania, 5475 in Rome and 891 in Monza sites. Moreover, the serological tests performed were 845 in Catania, 760 in Rome and 395 in Monza sites. A total of 6 SARS-CoV-2 infections were identified in Catania, 34 in Rome and 4 in Monza sites. Interestingly, the study of nosocomial transmission reported the highest incidence rate in Catania (4 per 10,000 person-day), while 0.7 per 10,000 person-day in Rome. During the study period seroprevalence declined by 17% among HWCs enrolled in Catania.
Conclusions
Our findings revealed low number of COVID-19 infections, with high COVID-19 vaccine coverage among HCWs. However, further analyses are needed to provide more robust estimates of vaccine effectiveness.
Key messages
Monitoring risk factors is useful to understand the pandemic scenario among high-risk groups.
A larger sample size and follow-up will improve public health vaccination strategies against COVID-19.</description><identifier>ISSN: 1101-1262</identifier><identifier>EISSN: 1464-360X</identifier><identifier>DOI: 10.1093/eurpub/ckac130.021</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Blood ; COVID-19 ; COVID-19 vaccines ; Disease control ; Disease prevention ; Disease transmission ; Effectiveness ; Hospitals ; Immunization ; Medical personnel ; Nosocomial infection ; Pandemics ; Public health ; Recruitment ; Risk factors ; Risk groups ; Saliva ; Serological tests ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine efficacy ; Vaccines ; Viral diseases</subject><ispartof>European journal of public health, 2022-10, Vol.32 (Supplement_3)</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,866,1586,1606,27873,27931,27932</link.rule.ids></links><search><creatorcontrib>Agodi, A</creatorcontrib><creatorcontrib>Rapisarda, V</creatorcontrib><creatorcontrib>Bonfanti, P</creatorcontrib><creatorcontrib>Rossi, M</creatorcontrib><creatorcontrib>De Gaetano Donati, K</creatorcontrib><creatorcontrib>Murri, R</creatorcontrib><creatorcontrib>Barchitta, M</creatorcontrib><title>European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals</title><title>European journal of public health</title><description>Background
Evaluating COVID-19 vaccine coverage and risk factors is useful to develop public health strategies against COVID-19 pandemic. In the framework of two studies commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Epiconcept, France, we reported findings about incidence and seroprevalence among healthcare workers (HCWs) enrolled from three Italian hospitals.
Methods
From July 2021 to date, the AOUP "G. Rodolico-San Marco" (Catania), the San Gerardo Hospital (Monza) and the Policlinico Gemelli (Rome) participated in the ECDC study to measure COVID-19 vaccine effectiveness. Catania and Rome also participated to the ECDC study of nosocomial transmission. HCWs were asked to complete a weekly questionnaire to report changes in health status and professional/personal exposures. At recruitment, a nasopharyngeal swab for RT-PCR and a blood sample for serology test were collected. Moreover, HCWs were followed-up with a weekly or bimonthly nasopharyngeal or saliva swabs. Blood samples were collected every one or two months.
Results
A total of 226 HCWs was enrolled from Catania, 330 from Rome and 132 from Monza in the COVID-19 vaccine effectiveness study. As of February 2022, PCR tests performed were 2270 in Catania, 5475 in Rome and 891 in Monza sites. Moreover, the serological tests performed were 845 in Catania, 760 in Rome and 395 in Monza sites. A total of 6 SARS-CoV-2 infections were identified in Catania, 34 in Rome and 4 in Monza sites. Interestingly, the study of nosocomial transmission reported the highest incidence rate in Catania (4 per 10,000 person-day), while 0.7 per 10,000 person-day in Rome. During the study period seroprevalence declined by 17% among HWCs enrolled in Catania.
Conclusions
Our findings revealed low number of COVID-19 infections, with high COVID-19 vaccine coverage among HCWs. However, further analyses are needed to provide more robust estimates of vaccine effectiveness.
Key messages
Monitoring risk factors is useful to understand the pandemic scenario among high-risk groups.
A larger sample size and follow-up will improve public health vaccination strategies against COVID-19.</description><subject>Blood</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Effectiveness</subject><subject>Hospitals</subject><subject>Immunization</subject><subject>Medical personnel</subject><subject>Nosocomial infection</subject><subject>Pandemics</subject><subject>Public health</subject><subject>Recruitment</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Saliva</subject><subject>Serological tests</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1101-1262</issn><issn>1464-360X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>7TQ</sourceid><recordid>eNqNkM1OwzAQhC0EEqXwApwscXZrO3ESc0Oh0EqVeuHvZjnuWqS0cbDjSrw9RukDoD3MHGZmpQ-hW0ZnjMpsDtH3sZmbL21YRmeUszM0YXmRk6ygH-fJM8oI4wW_RFch7Ciloqz4BJlF9K4H3eEwxG0LAQ8Ow1Hvox4A15u31SNhEh-1MW0HGKwFM7RH6CAE3HZ4Wb-He-whxP0QsPXugFeD3rdp8NOFvk0-XKMLmwRuTjpFr0-Ll3pJ1pvnVf2wJoaJjBFtilKUtql0IQRPR5stWFlVRc6hrKg0lDdbbaAqJGhuhTGWc24NNJLpxmZTdDfu9t59RwiD2rnou_RS8Urkkma5kCnFx5TxLgQPVvW-PWj_oxhVfzDVCFOdYKoEM5XIWHKx_0_-Fz8ueqQ</recordid><startdate>20221021</startdate><enddate>20221021</enddate><creator>Agodi, A</creator><creator>Rapisarda, V</creator><creator>Bonfanti, P</creator><creator>Rossi, M</creator><creator>De Gaetano Donati, K</creator><creator>Murri, R</creator><creator>Barchitta, M</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7TQ</scope><scope>C1K</scope><scope>DHY</scope><scope>DON</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20221021</creationdate><title>European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals</title><author>Agodi, A ; Rapisarda, V ; Bonfanti, P ; Rossi, M ; De Gaetano Donati, K ; Murri, R ; Barchitta, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1531-ac6757fb8a65525250bdef988642e7809c02bdace869ea2f5ccf222fceb91abf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Blood</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Effectiveness</topic><topic>Hospitals</topic><topic>Immunization</topic><topic>Medical personnel</topic><topic>Nosocomial infection</topic><topic>Pandemics</topic><topic>Public health</topic><topic>Recruitment</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Saliva</topic><topic>Serological tests</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agodi, A</creatorcontrib><creatorcontrib>Rapisarda, V</creatorcontrib><creatorcontrib>Bonfanti, P</creatorcontrib><creatorcontrib>Rossi, M</creatorcontrib><creatorcontrib>De Gaetano Donati, K</creatorcontrib><creatorcontrib>Murri, R</creatorcontrib><creatorcontrib>Barchitta, M</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agodi, A</au><au>Rapisarda, V</au><au>Bonfanti, P</au><au>Rossi, M</au><au>De Gaetano Donati, K</au><au>Murri, R</au><au>Barchitta, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals</atitle><jtitle>European journal of public health</jtitle><date>2022-10-21</date><risdate>2022</risdate><volume>32</volume><issue>Supplement_3</issue><issn>1101-1262</issn><eissn>1464-360X</eissn><abstract>Background
Evaluating COVID-19 vaccine coverage and risk factors is useful to develop public health strategies against COVID-19 pandemic. In the framework of two studies commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Epiconcept, France, we reported findings about incidence and seroprevalence among healthcare workers (HCWs) enrolled from three Italian hospitals.
Methods
From July 2021 to date, the AOUP "G. Rodolico-San Marco" (Catania), the San Gerardo Hospital (Monza) and the Policlinico Gemelli (Rome) participated in the ECDC study to measure COVID-19 vaccine effectiveness. Catania and Rome also participated to the ECDC study of nosocomial transmission. HCWs were asked to complete a weekly questionnaire to report changes in health status and professional/personal exposures. At recruitment, a nasopharyngeal swab for RT-PCR and a blood sample for serology test were collected. Moreover, HCWs were followed-up with a weekly or bimonthly nasopharyngeal or saliva swabs. Blood samples were collected every one or two months.
Results
A total of 226 HCWs was enrolled from Catania, 330 from Rome and 132 from Monza in the COVID-19 vaccine effectiveness study. As of February 2022, PCR tests performed were 2270 in Catania, 5475 in Rome and 891 in Monza sites. Moreover, the serological tests performed were 845 in Catania, 760 in Rome and 395 in Monza sites. A total of 6 SARS-CoV-2 infections were identified in Catania, 34 in Rome and 4 in Monza sites. Interestingly, the study of nosocomial transmission reported the highest incidence rate in Catania (4 per 10,000 person-day), while 0.7 per 10,000 person-day in Rome. During the study period seroprevalence declined by 17% among HWCs enrolled in Catania.
Conclusions
Our findings revealed low number of COVID-19 infections, with high COVID-19 vaccine coverage among HCWs. However, further analyses are needed to provide more robust estimates of vaccine effectiveness.
Key messages
Monitoring risk factors is useful to understand the pandemic scenario among high-risk groups.
A larger sample size and follow-up will improve public health vaccination strategies against COVID-19.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/eurpub/ckac130.021</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1101-1262 |
| ispartof | European journal of public health, 2022-10, Vol.32 (Supplement_3) |
| issn | 1101-1262 1464-360X |
| language | eng |
| recordid | cdi_proquest_journals_2854903459 |
| source | DOAJ Directory of Open Access Journals; PAIS Index; Access via Oxford University Press (Open Access Collection); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Blood COVID-19 COVID-19 vaccines Disease control Disease prevention Disease transmission Effectiveness Hospitals Immunization Medical personnel Nosocomial infection Pandemics Public health Recruitment Risk factors Risk groups Saliva Serological tests Serology Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines Viral diseases |
| title | European studies to evaluate COVID-19 vaccine effectiveness in HCWs: results from Italian hospitals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T13%3A22%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=European%20studies%20to%20evaluate%20COVID-19%20vaccine%20effectiveness%20in%20HCWs:%20results%20from%20Italian%20hospitals&rft.jtitle=European%20journal%20of%20public%20health&rft.au=Agodi,%20A&rft.date=2022-10-21&rft.volume=32&rft.issue=Supplement_3&rft.issn=1101-1262&rft.eissn=1464-360X&rft_id=info:doi/10.1093/eurpub/ckac130.021&rft_dat=%3Cproquest_cross%3E2854903459%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2854903459&rft_id=info:pmid/&rft_oup_id=10.1093/eurpub/ckac130.021&rfr_iscdi=true |